Evaluation of the immunogenicity and reactogenicity of a DTPa-HBV-IPV combination vaccine Co-administered with a hib conjugate vaccine either as a single injection of a hexavalent combination or as two separate injections at 3, 5 and 11 months of age

References

• Bonanni P, Bergamini M. Factors influencing vaccine uptake in Italy. Vaccine 2002; 20: S8–12.
   Google Scholar
• Ellis RE. Development of combination vaccines. Vaccine 1999; 17: 1635–2.
   PubMed Web of Science ®Google Scholar
• Hadler SC. Cost benefit of combining antigens. Biologicals 1994; 22: 415–8.
   PubMedGoogle Scholar
• André FE. Development and clinical application of new polyvalent combined paediatric vaccines. Vaccine 1999; 17: 1620–7.
   PubMed Web of Science ®Google Scholar
• Gylca R, Gylca V, Benes O, Melnic A, Chicu V, Weisbecker C. A new DTPa-HBV-IPV vaccine co-administered with Hib, compared to a commercially available DTPw-IPV/Hib vaccine coadministered with HBV, given at 6, 10 and 14 weeks following HBVat birth. Vaccine 2000; 19: 825–33.
   PubMedGoogle Scholar
• Zepp F, Schuind A, Meyer C, Sänger R, Kaufhold A, Willems P. Safety and reactogenicity of a novel DTPa-HBV-IPV combined vaccine given with commercial Hib vaccines in comparison with separate concomitant administration of DTPa, Hib, and OPV vaccines in infants. Pediatrics 2002; 109: 1–8.
   Google Scholar
• Yeh SH, Ward JI, Partridge S, Marcy SM, Lee H, Jing J, et al. Safety and immunogenicity of a pentavalent diphtheria, tetanus, pertussis, hepatitis B and polio combination vaccine in infants. Pediatr Infect Dis 2001; 20: 973–80.
   Google Scholar
• Capiau C, Poolman J, Hoet B, Bogaerts H, Andre F. Development and clinical testing of multivalent vaccines based on a diphtheria-tetanus-acellular pertussis vaccine: difficulties encountered and lessons learned. Vaccine 2003; 21: 2273–87.
   Google Scholar
• Schmitt HJ, Knuf M, Ortiz E, Sanger R, Uwamwezi MC, Kaufhold A. Primary vaccination of infants with diphtheria-tetanus-acellular pertussis-hepatitis B virus- inactivated polio virus and Haemophilus influenzae type b vaccines given as either separate or mixed injections. J Pediatr 2000; 137: 304–12.
   PubMed Web of Science ®Google Scholar
• Aristegui J, Dal-Ré R, Diez-Delgado JD, Marés J, Casanovas JM, Garcia-Corbeira P, et al. Comparison of the reactogenicity and immunogenicity of a combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio (DTPa–HBV–IPV) vaccine, mixed with the Haemophilus influenzae type b (Hib) conjugate vaccine and administered as a single injection, with the DTPa–IPV/Hib and hepatitis B vaccines administered in 2 simultaneous injections to infants at 2, 4 and 6 months of age. Vaccine 2003; 21: 359–600.
   Google Scholar
• Schmitt HJ, Booy R, Weil-Olivier C, Van Damme P, Cohen R, Peltola H. Child vaccination policies in Europe: a report from the Summits of Independent European Vaccination Experts. Lancet Infect Dis 2003; 3: 103–8.
   Google Scholar
• Recommendations of the Advisory Committee on Immunization Practices (ACIP) Update: Vaccine Side-Effects, Adverse Reactions, Contraindications, and Precautions Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb Mortal Wkly Rep 1996; 45: 1–35.
   PubMedGoogle Scholar
• van Savage J, Decker MD, Edwards KM, Sell SH, Karzon DT. Natural history of pertussis antibody in the infant and effect on vaccine response. J Infect Dis 1990; 161: 487–92.
   Google Scholar
• Rappuoli R, Locht C, Poolman J, Andre F, Dougan G. European Commission COST/STD Initiative, Report of the Expert Panel VIII. New vaccines, especially new combined vaccines. Vaccine 1996; 14: 691–700.
   Google Scholar
• Meyerhoff A, Weniger B, Jacobs RJ. Economic value to parents of reducing the pain and emotional distress of childhood vaccine injections. Pediatr Infect Dis J 2001; 20(Suppl 1): S57–62.
   Google Scholar
• Avdicová M, Prikazsky V, Hudeckova H, Schuerman L, Willems P. Immunogenicity and reactogenicity of a novel hexavalent DTPa-HBV-IPV/Hib vaccine compared to separate concomitant injections of DTPa-IPV/Hib and HBV vaccines, when administered according to a 3, 5 and 11 month vaccination schedule. Eur J Pediatr 2002; 161: 581–7.
   PubMed Web of Science ®Google Scholar
• Taranger J, Trollfors B, Knutsson N, Sundh V, Lagergaerd T, Estergaard E. Vaccination of infants with a 4-dose and a 3-dose vaccination schedule. Vaccine 2000; 18: 884–91.
   Google Scholar
• Carlsson R-M, Claesson BA, Selstam U, Fagerlund E, Granström M, Blondeau C. Safety and immunogenicity of a combined diphtheria-tetanus-acellular pertussis-inactivated polio vaccine-Haemophilus influenzae type b vaccine administered at 2, 4, 6, 13 or 3,5, 12 months of age, Pediatr. Infect Dis J 1998; 17: 1026–33.
   Google Scholar
• Eskola J, Olander R-M, Hovi T, Litmanen L, Peltola S, Kayhty H. Randomized trial of the effect of co-administration with acellular pertussis DTP vaccine on immunogenecity of Haemophilus influenzae type conjugate vaccine. Lancet 1996; 348: 1688–92.
   PubMed Web of Science ®Google Scholar
• Pichichero ME, Passador S. Administration of combined diphtheria and tetanus toxoids and pertussis vaccine, hepatitis B vaccine, and Haemophilus influenzae type b (Hib) vaccine to infants and response to a booster dose of Hib conjugate vaccine. Clin Infect Dis 1997; 25: 1378–84.
   PubMed Web of Science ®Google Scholar
• Bell F, Heath P, Shackley F, MacLennan J, Shearstone N, Diggle L, et al. Effect of combination with an acellular pertussis, diphtheria, tetanus vaccine on antibody response to Hib vaccine (PRP-T). Vaccine 1998; 16: 637–42.
   PubMed Web of Science ®Google Scholar
• Eskola J, Ward J, Dagan R, Goldblatt D, Zepp F, Siegrist CA. Combined vaccination of Haemophilus influenzae type b conjugate and diphtheria-tetanus-pertussis containing acellular pertussis. Lancet 1999; 354: 2063–8.
   PubMed Web of Science ®Google Scholar
• Halperin SA, King J, Law B, Mills E, Willems P. Safety and immunogenicity of Haemophilus influenzae-tetanus toxoid conjugate vaccine given separately or in combination with a 3- component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine for the first 4 doses. Clin Infect Dis 1999; 28: 995–1001.
   Google Scholar
• Poolman J, Kaufhold A, De Grave D, Goldblatt D. Clinical relevance of lower Hib response in DTPa-based combination vaccines. Vaccine 2001; 19: 2280–5.
   PubMed Web of Science ®Google Scholar
• Mäkelä PH, Käyhty H. Evolution of conjugate vaccines. Expert Rev Vaccines 2002; 1: 399–410.
   PubMedGoogle Scholar
• Sänger R, the German 095-study group, Mächler G, Meurice F, Schuerman L Persistence of antibodies in children primed with 2 different hexavalent diphtheria-tetanus-acellular pertussis-HBV-IPV-Hib vaccines and evaluation of booster vaccination. ESPID 2004, Tampere, Finland.
   Google Scholar